» Articles » PMID: 26496640

The Direct Actions of GABA, 2'-Methoxy-6-Methylflavone and General Anaesthetics at β3γ2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries

Overview
Journal PLoS One
Date 2015 Oct 27
PMID 26496640
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

2'-Methoxy-6-methylflavone (2'MeO6MF) is an anxiolytic flavonoid which has been shown to display GABAA receptor (GABAAR) β2/3-subunit selectivity, a pharmacological profile similar to that of the general anaesthetic etomidate. Electrophysiological studies suggest that the full agonist action of 2'MeO6MF at α2β3γ2L GABAARs may mediate the flavonoid's in vivo effects. However, we found variations in the relative efficacy of 2'MeO6MF (2'MeO6MF-elicited current responses normalised to the maximal GABA response) at α2β3γ2L GABAARs due to the presence of mixed receptor populations. To understand which receptor subpopulation(s) underlie the variations observed, we conducted a systematic investigation of 2'MeO6MF activity at all receptor combinations that could theoretically form (α2, β3, γ2L, α2β3, α2γ2L, β3γ2L and α2β3γ2L) in Xenopus oocytes using the two-electrode voltage clamp technique. We found that 2'MeO6MF activated non-α-containing β3γ2L receptors. In an attempt to establish the optimal conditions to express a uniform population of these receptors, we found that varying the relative amounts of β3:γ2L subunit mRNAs resulted in differences in the level of constitutive activity, the GABA concentration-response relationships, and the relative efficacy of 2'MeO6MF activation. Like 2'MeO6MF, general anaesthetics such as etomidate and propofol also showed distinct levels of relative efficacy across different injection ratios. Based on these results, we infer that β3γ2L receptors may form with different subunit stoichiometries, resulting in the complex pharmacology observed across different injection ratios. Moreover, the discovery that GABA and etomidate have direct actions at the α-lacking β3γ2L receptors raises questions about the structural requirements for their respective binding sites at GABAARs.

Citing Articles

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.

Anderson L, Absalom N, Abelev S, Low I, Doohan P, Martin L Epilepsia. 2019; 60(11):2224-2234.

PMID: 31625159 PMC: 6900043. DOI: 10.1111/epi.16355.


Concatenated γ-aminobutyric acid type A receptors revisited: Finding order in chaos.

Yu Liao V, Chua H, Kowal N, Chebib M, Balle T, Ahring P J Gen Physiol. 2019; 151(6):798-819.

PMID: 30988061 PMC: 6572006. DOI: 10.1085/jgp.201812133.


Functional genomics of epilepsy-associated mutations in the GABA receptor subunits reveal that one mutation impairs function and two are catastrophic.

Absalom N, Ahring P, Liao V, Balle T, Jiang T, Anderson L J Biol Chem. 2019; 294(15):6157-6171.

PMID: 30728247 PMC: 6463728. DOI: 10.1074/jbc.RA118.005697.


α subunits in GABA receptors are dispensable for GABA and diazepam action.

Wongsamitkul N, Maldifassi M, Simeone X, Baur R, Ernst M, Sigel E Sci Rep. 2017; 7(1):15498.

PMID: 29138471 PMC: 5686171. DOI: 10.1038/s41598-017-15628-7.


Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface.

Che Has A, Absalom N, van Nieuwenhuijzen P, Clarkson A, Ahring P, Chebib M Sci Rep. 2016; 6:28674.

PMID: 27346730 PMC: 4921915. DOI: 10.1038/srep28674.


References
1.
Sigel E, Buhr A . The benzodiazepine binding site of GABAA receptors. Trends Pharmacol Sci. 1998; 18(11):425-9. DOI: 10.1016/s0165-6147(97)01118-8. View

2.
Brickley S, Cull-Candy S, Farrant M . Single-channel properties of synaptic and extrasynaptic GABAA receptors suggest differential targeting of receptor subtypes. J Neurosci. 1999; 19(8):2960-73. PMC: 6782265. View

3.
Harpsoe K, Ahring P, Christensen J, Jensen M, Peters D, Balle T . Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci. 2011; 31(30):10759-66. PMC: 6623092. DOI: 10.1523/JNEUROSCI.1509-11.2011. View

4.
Knoflach F, Backus K, Giller T, Malherbe P, Pflimlin P, Mohler H . Pharmacological and Electrophysiological Properties of Recombinant GABAA Receptors Comprising the alpha3, beta1 and gamma2 Subunits. Eur J Neurosci. 1992; 4(1):1-9. DOI: 10.1111/j.1460-9568.1992.tb00103.x. View

5.
Luscher B, Fuchs T, Kilpatrick C . GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron. 2011; 70(3):385-409. PMC: 3093971. DOI: 10.1016/j.neuron.2011.03.024. View